BEDFORD, Mass., Sept. 19, 2019 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced commercialization of the HemosIL AcuStar ADAMTS13 Activity Assay in the European Union and other ...
The groundbreaking initiative, called FAST4TMA, will be launched for patients across the U.S. on June 24, 2023. Founded in 2014 as a grassroots effort, USTMA is on a mission to improve outcomes in ...
Prophylaxis With Recombinant ADAMTS13 Demonstrates Superiority vs Standard Therapy in Congenital TTP
The multinational, open-label, controlled, randomized, crossover, phase 3 TAK-755 (NCT03393975) trial demonstrated superior efficacy and safety of recombinant ADAMTS13 as prophylaxis in patients with ...
Please provide your email address to receive an email when new articles are posted on . Mean maximum ADAMTS13 activity after recombinant ADAMTS13 exceeded 100%. Markedly fewer patients receiving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results